Non-Alcoholic Steatohepatitis (NASH) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026

Non-Alcoholic Steatohepatitis (NASH) Emerging Therapy and TPP Insights

Thelansis’s “Non-Alcoholic Steatohepatitis (NASH) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Non-Alcoholic Steatohepatitis (NASH) Overview

Non-alcoholic steatohepatitis, now more accurately referred to in current clinical and regulatory guidance as metabolic dysfunction associated steatohepatitis, is a progressive liver disease that develops when fat buildup in the liver, closely tied to obesity, insulin resistance, and related metabolic conditions, advances into inflammation and scarring that can eventually lead to cirrhosis and liver failure. That naming shift reflects a broader move away from defining the disease by what it is not, namely alcohol related, toward defining it by its actual metabolic drivers, a change now widely adopted across scientific literature, regulatory filings, and drug labeling. Clinically, treatment has evolved just as significantly, moving from a landscape with no approved pharmacologic therapy toward one featuring a liver-targeted oral therapy that activates a specific thyroid hormone receptor pathway, followed by a GLP-1 receptor agonist already established in diabetes and obesity care extending its benefits into liver health. Diagnosis has also evolved, increasingly relying on non-invasive blood-based and imaging tools to stage fibrosis rather than defaulting to biopsy.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)